Business News • MarketWire • Radient Phamacueticals Strategic Partner Jaiva Technologies Plans to Submit Application for Phase II Human Clinical Trials for Non-Small Cell Lung Carcinoma; Advancing Commercialization of RPC's CIT(TM) Cancer Vaccine in India |
Radient Phamacueticals Strategic Partner Jaiva Technologies Plans to Submit Application for Phase II Human Clinical Trials for Non-Small Cell Lung Carcinoma; Advancing Commercialization of RPC's CIT(TM) Cancer Vaccine in India |
|
|
Radient Phamacueticals Strategic Partner Jaiva Technologies Plans to Submit Application for Phase II Human Clinical Trials for Non-Small Cell Lung Carcinoma; Advancing Commercialization of RPC's CIT(TM) Cancer Vaccine in India
TUSTIN, CA--(Marketwire - June 24, 2010) - Radient Pharmaceuticals Corporation (NYSE Amex: RPC), a US-based pharmaceutical company, and Jaiva Technologies, Inc. ("Jaiva"), a US-based biotechnology company focused on the research and development, distribution, marketing and sales of promising third-party healthcare technology products, including RPC's CIT cancer therapy and vaccine, announced today that Jaiva plans to submit a clinical trial application to the Central Drugs Standard Control Organization (CDSCO) in India to commence human phase II trials for RPC's Combination Immunogene Therapy (CIT) technology as a vaccine therapy for non-small cell lung carcinoma (NSCLC).
View More : http://www.marketwire.com/mw/release.do?id=1281149&sourceType=3
|
|
|